ImmuPharma plc (LON:IMM – Get Free Report) dropped 14.6% during trading on Tuesday . The company traded as low as GBX 3.20 ($0.04) and last traded at GBX 3.20 ($0.04). Approximately 13,200,714 shares traded hands during mid-day trading, a decline of 53% from the average daily volume of 28,314,303 shares. The stock had previously closed at GBX 3.75 ($0.05).
ImmuPharma Trading Down 14.6 %
The firm has a market capitalization of £13.33 million, a PE ratio of -320.00 and a beta of 1.53. The business has a 50-day moving average of GBX 1.48 and a 200 day moving average of GBX 1.66.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Featured Articles
- Five stocks we like better than ImmuPharma
- Why Are These Companies Considered Blue Chips?
- The Fed Is More Likely to Hike Than Cut Rates in 2025
- Stock Analyst Ratings and Canadian Analyst Ratings
- Investors Navigate Uncertainty by Seeking Refuge in Gold and Oil
- How to Invest in the Best Canadian Stocks
- Archer Aviation Shares Slide, Now Bargain Priced for 2025
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
